Develops medicines for patients with autoimmune diseases and pulmonary hypertension through subsidiaries, and incubates discovery-stage and healthcare technology companies.
10-K for FY2025, filed May 20, 2026Roivant is a biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of…View ↗
Roivant earns money by licensing intellectual property, receiving payments tied to development milestones and royalties when licensees make sales, and providing technology through subscription and service fees.
10-K for FY2025, filed May 20, 2026
$8.3M
10-K for FY2025, filed May 20, 2026
$8.3M ↗
Drug licensees pay Roivant for intellectual-property rights; technology customers use subscription and service offerings. U.S. healthcare professionals can prescribe LISRAYA, with prescriptions submitted through its enrollment site.
10-K for FY2025, filed May 20, 2026 8-K, filed Aug 27, 2026LISRAYA, a first-in-class TYK2/JAK1 inhibitor, is the first and only targeted therapy approved for dermatomyositis. LISRAYA is proven to…View ↗
No. It lost $299.8M in FY2026.
10-Q for Q2 FY2026, filed Nov 9, 2026
−$191.6MView ↗
8-K, filed Aug 27, 2026
On August 27, 2026, Roivant Sciences Ltd. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration had…View ↗
Shrinking. Revenue fell 85% in 4 years, from $55.3M in FY2022 to $8.3M in FY2026, about 38% a year.
From marketed product to development pipeline
The older report included a commercially launched medicine alongside its drug candidates; the latest report describes Roivant's pipeline and says it had no products approved for commercial sale.
10-K for FY2022, filed Jun 28, 2022 10-K for FY2025, filed May 20, 2026Product/Product Candidate Indication Vant Modality Phase VTAMA® (tapinarof) Psoriasis Dermavant Topical Commercial VTAMA® (tapinarof)…View ↗
Loading...